A promising molecular pair has offered hope that could lead to the development of a new treatment to slow down Parkinson's disease, a study has found.
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting 7 to 10 million people worldwide. Patients with the illness have reduced levels of dopamine in the brain, causing them to have difficulty controlling motor movements, with symptoms such as tremor and rigidity of muscles in hands, arms, and legs. They can also develop some non-motor symptoms, like sleep disturbance, depression, and loss of smell.
Through laboratory investigations and in vivo experiments, the team found that the 'molecular pair', Prostaglandin E1 (PGE1) - a type of hormone - and Prostaglandin A1 (PGA1), can be the key to boosting dopamine levels and slowing Parkinson's disease.
PGE1 and PGA1 do so by binding to Nurr1, a class of proteins crucial to the development and maintenance of dopamine in the brain.
Their binding causes Nurr1 to be activated, resulting in a marked increase in dopamine production while preventing dopamine-producing brain cells from dying. After activating Nurr1, the mice with Parkinson's disease showed significant improvements in their motor functions.
Although much research still needs to be done, these findings could provide a new avenue for the creation of Nurr1-activating drugs to combat Parkinson's disease - an illness with no cure currently. While there are already treatment methods like dopamine-raising medication or deep brain stimulation using electric currents, these treatments have side-effects and can only address the patient's symptoms, not slow down, or halt the disease.
The senior author said, "Considering the essential function of Nurr1, we have been searching for its activating molecules in the body. Finally, we have successfully identified that PGE1/PGA1 is the molecular pair that acts specifically on Nurr1 and can lead to neuroprotective effects on the brain."
"Given that all candidate Parkinson's drugs have failed to show neuroprotective abilities in clinical trials, our findings may offer an opportunity to design mechanism-based disease-modifying therapeutics to treat Parkinson's disease with little side effect."
The findings were published in the peer-reviewed journal Nature Chemical Biology.
One of a number of hormone-like substances in the body, Prostaglandins are responsible for a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.
Their regulatory roles in activating the dopamine function of Nurr1 have not been studied until now.
To identify and characterise how PGE1/PGA1 activates Nurr1, the team of researchers used nuclear magnetic resonance and X-ray crystallography to decipher the structures of the molecules involved, successfully unveiling details of how PGA1 binding leads to the activation of Nurr1 for the first time.
These findings from experiments on cells were then supported by in vivo experiments with experimentally induced Parkinson's disease, which showed significant improvements in their motor functions when PGE1 and PGA1 were administered.
The senior author said, "By uncovering the molecular interactions, we gain insights into the biological function and regulation of Nurr1 in health and disease such as Parkinson's disease. Our findings in this study are adding to what we know about how dopamine neurons function and point towards the development of novel therapeutics of Parkinson's disease."
A co-author said, "PGA1 is not a new kid on the block, but a molecule known to exhibit anti-inflammation and anti-tumour properties. Prostaglandins like PGE1 are available for clinical use, for example in obstetrics cases. This means that the compound can potentially be re-positioned to treat Parkinson's patients, which can accelerate the time needed to take an experimental drug to the clinic."
The scientists are now looking to design a synthetic form of PGE1/PGA1 and to validate it as a potential new drug that can target Nurr1, thereby halting or reversing the onset of Parkinson's disease.
https://media.ntu.edu.sg/NewsReleases/Pages/newsdetail.aspx?news=13a44543-8423-46dd-b79f-50e6847c1994&fbclid=IwAR303TfPI4khFmuA1uHLI944f3FQa1RfTIwabZ7VJrxvYfDV2nrj-OToKG8
https://www.nature.com/articles/s41589-020-0553-6
Prostaglandins offer potential for Parkinson's treatment
- 1,125 views
- Added
Edited
Latest News
Protein that helps COVID-19…
By newseditor
Posted 26 Jul
Spinal Muscular Atrophy (SM…
By newseditor
Posted 26 Jul
Link between bowel movement…
By newseditor
Posted 26 Jul
Inhibition of IL-11 signall…
By newseditor
Posted 25 Jul
Brain changes linked to obe…
By newseditor
Posted 25 Jul
Other Top Stories
Alternate splicing sequence determinants identified!
Read more
MicroRNAs regulating cholesterol and triglyceride homeostasis ident…
Read more
RNA Controls Poly-glutamine Protein Phase Transitions
Read more
Nuclear membrane repairs the 'dark matter' of DNA
Read more
Transmembrane protein sorting driven by membrane curvature
Read more
Protocols
A systems biology approach…
By newseditor
Posted 24 Jul
quantms: a cloud-based pipe…
By newseditor
Posted 22 Jul
Emerging tools and best pra…
By newseditor
Posted 19 Jul
Directly selecting cell-typ…
By newseditor
Posted 17 Jul
PUFFFIN: an ultra-bright, c…
By newseditor
Posted 16 Jul
Publications
Hepatocyte-intrinsic SMN de…
By newseditor
Posted 26 Jul
Aberrant bowel movement fre…
By newseditor
Posted 26 Jul
A pseudoautosomal glycosyla…
By newseditor
Posted 26 Jul
Microglia protect against a…
By newseditor
Posted 26 Jul
Rigor and reproducibility i…
By newseditor
Posted 26 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar